Skip to main content
Figure 1 | Molecular Cancer

Figure 1

From: Signal transducer and activator of transcription 3 activation up-regulates interleukin-6 autocrine production: a biochemical and genetic study of established cancer cell lines and clinical isolated human cancer cells

Figure 1

Autocrine IL-6 induced Stat3 activation and paclitaxel resistance in AS2 cells. (A) AS2 cells constitutively secreted IL-6. AS2 cells were seeded for 24 hours before medium replacement. Culture supernatants were collected 1, 3, 8, or 24 hours after medium replacement and the IL-6 levels were detected by ELISA. This graph shows the results as mean ± SEM. Student's t tests, ***p < 0.001. (B) Autocrine IL-6 induced Stat3 activation in AS2 cells. AS2 cells were seeded for 24 hours before medium replacement. Cell lysates were collected 1, 3, 8, or 24 hours after medium replacement. The activation of Stat3 was evaluated by Western blot analysis. (C) Autocrine IL-6 rendered AS2 cells resistant to paclitaxel. AS2 cells were seeded for 24 hours and then treated as following: (1) cells without pretreatment and treated with varying doses of the chemotherapeutic agent palitaxel only for 72 hours, (2) cells pretreated with exogenous IL-6 (20 ng/ml) for 1 hour and then cotreated with exogenous IL-6 + paclitaxel for 72 hours, and (3) cells pretreated with anti-IL-6 receptor neutralizing antibody (anti-IL-6R) (5 μg/ml) for 1 hour and then cotreated with anti-IL-6R + paclitaxel for 72 hours. The viability of AS2 cells was analyzed by MTT assay. This graph shows the results as mean ± SEM. Student's t tests, ***p < 0.001.

Back to article page